The analyses being presented provide important information about CAPLYTA's efficacy, safety and tolerability profile in patients with bipolar I and II disorder and in patients with major depressive disorder (MDD) suffering from a major depressive episode and exhibiting mixed features. ASCP Presentations: CAPLYTA® (lumateperone) is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive thera ...